What are the key provisions of China's new trade rules announced ahead of the Trump-Xi summit, and how do they target U.S. 'derisking' efforts?

China's new trade rules, announced just weeks before the May 14–15 Trump-Xi summit, lay the legal groundwork for investigating and punishing foreign companies that suspend normal transactions with Chinese citizens or organizations—such as by shifting sourcing away from China. The rules do not specify industries but authorize Chinese agencies to develop a 'key sectors list' to safeguard the circulation of raw materials, technology, equipment, and other products. As stated in the body, these measures 'effectively push U.S. and other foreign businesses in the other direction' from the Trump administration's 'derisking' policy, which urges reducing dependence on Chinese goods—especially in strategic areas like critical minerals and medicines.

How has the Trump administration responded publicly to China's new trade rules, and what does this silence suggest according to analysts and officials?

The Trump administration has responded with 'uncharacteristically muted' silence: U.S. officials have not spoken publicly about Beijing's move, the White House spokesman declined to address the measures directly (stating only that the administration 'will continue to leverage every bit of America's economic might'), and the Treasury Department and U.S. Trade Representative did not respond to Reuters' requests for comment. According to an anonymous U.S. official cited in the article, the timing suggests Beijing is 'testing how eager the White House is to maintain the pause in the trade war'; Craig Singleton of FDD warned that 'Washington's response so far has been silence. That risks signaling weakness,' while noting the administration appeared to want to avoid public escalation ahead of the summit.

White House Quiet as China Ramps Up Trade Leverage Before Trump-Xi Summit

Apr 29, 2026

China enacted new trade rules penalizing firms reducing sourcing dependence, impacting critical minerals and pharmaceutical supply chains. The White House maintains silence ahead of the Trump-Xi summit despite industry concerns over supply coercion.

reuters

Trump administration ends Medicare drug subsidy, Trump announces deal for Hamas to disarm in Gaza, border crisis

2026-04-22

US Hopes for Wider Farm Goods Purchase Deal with China During Trump Visit, Says Greer

2026-04-26

China Expands Economic Pressure Toolkit Under Cover of Trade Truce with Trump

2026-04-29

White House Quiet as China Ramps Up Trade Leverage Before Trump-Xi Summit

2026-05-06

Chinese Exporters 'Numb' to U.S. Threats as Trump Set to Visit

2026-05-07